[Gujarat, India — 2025-10-09] — Premier Medical Corporation is pleased to announce the launch of the First Response® Sickle Cell Detection Card Test, a rapid, qualitative in vitro diagnostic solution designed to support early screening of hemoglobin variants Type-A and Type-S in both laboratory and point-of-care settings.

Developed for use by trained healthcare professionals, this innovative card-based test enables reliable detection of hemoglobin variants associated with sickle cell disease and sickle cell trait. Its straightforward, easy-to-interpret format enhances usability while maintaining exceptional diagnostic accuracy.

With >99% sensitivity and >99% specificity, the First Response® Sickle Cell Detection Card Test provides the dependable performance clinicians need to support timely medical decisions. Delivering rapid results within 5–10 minutes, it enables fast screening in high-throughput environments and resource-limited settings.

Key Product Features

• Qualitative detection of hemoglobin variants Type-A and Type-S

• Sensitivity >99%

• Specificity >99%

• Rapid results within 5–10 minutes

• Suitable for laboratory and point-of-care testing

• Whole blood specimen

• Stable storage at 4°C – 30°C

• Simple, user-friendly card-based format

Premier Medical Corporation continues to advance high-quality diagnostic technologies that strengthen early detection and improve health outcomes globally.

For more information about the First Response® Sickle Cell Detection Card Test, please contact our customer support team or visit our product pages.